Latest VRTX news and sentiment

Vertex Pharmaceuticals Eyes Renal Growth With Key PDUFA, Pipeline Catalysts Ahead

Vertex Pharmaceuticals Highlights Catalyst-Rich Pipeline Beyond Cystic Fibrosis

Vertex Pharmaceuticals Maps Growth Beyond CF at Cantor Conference

Key Points Interested in Vertex Pharmaceuticals Incorporated? Here are five stocks we like better. Vertex is broadening beyond cystic fibrosis through its Crinetics acquisition, adding PALSONIFY and the late-stage congenital adrenal hyperplasia drug atumelnant, which the company estimates could generate a combined $5 billion in peak sales. Renal pipeline catalysts are approaching: povetacicept has a November 30 FDA decision date for IgA nephropathy, while Phase II data for inaxaplin are expected before year-end and its Phase III interim analysis is planned for early 2027. JOURNAVX is becoming

Vertex Pharmaceuticals Incorporated (VRTX): Crinetics Acquisition Creates a New Growth Engine Beyond Cystic Fibrosis

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) could be positioning itself for its next major phase of growth following its roughly $10 billion acquisition of Crinetics Pharmaceuticals. The deal gives the company immediate exposure to the endocrinology market and provides a new commercial platform beyond its established cystic fibrosis franchise. Vertex Expands Into Endocrinology On September 3, Citigroup analyst Geoff Meacham highlighted the strategic importance of the Crinetics acquisition, arguing it could diversify Vertex's business while complementing its existing cystic fibrosis franc

Q2 Rundown: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs Other Therapeutics Stocks

Q2 Rundown: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs Other Therapeutics Stocks As the Q2 earnings season wraps, let's dig into this quarter's best and worst performers in the therapeutics industry, including Vertex Pharmaceuticals (NASDAQ:VRTX) and its peers. Over the next few years, therapeutic companies, which develop a wide variety of treatments for diseases and disorders, face strong tailwinds from advancements in precision medicine (including the use of AI to improve hit rates) and growing demand for treatments targeting rare diseases. However, headwinds such as rising scrutiny over drug p

Goldman Sachs Just Added Vertex Pharmaceuticals to Its Conviction List. Here's the Bull Case for the Big Biotech Stock

Vertex Pharmaceuticals (VRTX) Suffers a Larger Drop Than the General Market: Key Insights

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $528.90, marking a -3.15% move from the previous day. The stock trailed the S&P 500, which registered a daily loss of 0.58%. Meanwhile, the Dow experienced a drop of 1.18%, and the technology-dominated Nasdaq saw a decrease of 0.32%. Heading into today, shares of the drugmaker had gained 4.24% over the past month, outpacing the Medical sector's gain of 2.73% and the S&P 500's loss of 0.36%. Market participants will be closely following the financial results of Vertex Pharmaceuticals in its upcoming release. On that day, Ver

Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know

Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Shares of this drugmaker have returned +4.2% over the past month versus the Zacks S&P 500 composite's -0.4% change. The Zacks Medical - Biomedical and Genetics industry, to which Vertex belongs, has gained 5.8% over this period. Now the key question is: Where could the stock be headed in the near term? Although media reports or rumors about a significant change in a company

How Is Vertex Pharmaceuticals' Stock Performance Compared to Other Biotech Stocks?

Vertex (VRTX) Stock Trades At A Premium On Earnings Yet Looks Fair On Broader Checks

Vertex Pharmaceuticals stock has delivered strong multi year gains, and current valuation checks suggest the shares now look closer to fairly priced than clearly cheap or clearly expensive. Vertex Pharmaceuticals has returned 184.9% over the past 5 years, which puts extra focus on whether the current price still offers an appealing entry point for new money. Expectations for continued revenue and cash flow growth from its existing treatment portfolio can support today's valuation, while any setback in clinical execution or pricing pressure may weigh on how durable those cash flows look. The br

Vertex Completes $10 Billion Crinetics Acquisition, Adding Rare Endocrine Growth Platform

Vertex Pharmaceuticals Closes Crinetics Pharmaceuticals Acquisition

Crinetics acquisition completed September 1, 2026 Charles Wagner, EVP, Chief Operating and Financial Officer to take on expanded COO role overseeing integration of Crinetics, effective immediately As part of a planned transition, Jonathan Poole, current SVP Finance, will be appointed EVP, CFO, effective January 1, 2027, and Mr. Wagner will continue as EVP, COO Jasper van Grunsven to join Vertex as EVP, Chief Pain and New Product Planning Officer in September BOSTON, September 01, 2026--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the successful completion

Vertex to Participate in Upcoming September Investor Conferences

BOSTON, August 26, 2026--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in four upcoming investor conferences. Susie Lisa, Senior Vice President of Investor Relations and Manisha Pai, Executive Director of Investor Relations, will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026, at 4:30 p.m. EDT. Susie Lisa and Manisha Pai will also participate in a fireside chat at the 2026 Cantor Global Healthcare Conference on Thursday, September 10, 2026, at 2:10 p.m. EDT. Reshm